- Home
- NUKK vs CRDL Comparison
NUKK vs CRDL Comparison
Compare NUKK & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUKK
- CRDL
- Stock Information
- Founded
- NUKK 2013
- CRDL 2017
- Country
- NUKK United States
- CRDL Canada
- Employees
- NUKK N/A
- CRDL N/A
- Industry
- NUKK Blank Checks
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NUKK Finance
- CRDL Health Care
- Exchange
- NUKK Nasdaq
- CRDL Nasdaq
- Market Cap
- NUKK 100.0M
- CRDL 90.4M
- IPO Year
- NUKK N/A
- CRDL N/A
- Fundamental
- Price
- NUKK $7.12
- CRDL $1.15
- Analyst Decision
- NUKK
- CRDL Strong Buy
- Analyst Count
- NUKK 0
- CRDL 2
- Target Price
- NUKK N/A
- CRDL $9.00
- AVG Volume (30 Days)
- NUKK 2.6M
- CRDL 835.2K
- Earning Date
- NUKK 11-14-2025
- CRDL 11-13-2025
- Dividend Yield
- NUKK N/A
- CRDL N/A
- EPS Growth
- NUKK N/A
- CRDL N/A
- EPS
- NUKK N/A
- CRDL N/A
- Revenue
- NUKK N/A
- CRDL N/A
- Revenue This Year
- NUKK N/A
- CRDL N/A
- Revenue Next Year
- NUKK N/A
- CRDL N/A
- P/E Ratio
- NUKK N/A
- CRDL N/A
- Revenue Growth
- NUKK N/A
- CRDL N/A
- 52 Week Low
- NUKK $1.30
- CRDL $0.77
- 52 Week High
- NUKK $78.32
- CRDL $2.24
- Technical
- Relative Strength Index (RSI)
- NUKK 45.16
- CRDL 56.07
- Support Level
- NUKK $6.71
- CRDL $1.14
- Resistance Level
- NUKK $8.70
- CRDL $1.38
- Average True Range (ATR)
- NUKK 1.81
- CRDL 0.08
- MACD
- NUKK -0.46
- CRDL 0.01
- Stochastic Oscillator
- NUKK 5.41
- CRDL 45.15
About NUKK Nukkleus Inc.
Nukkleus Inc is a financial technology company that is focused on providing software and technology solutions. The company's operating segment includes General support services and Financial services. General support services include providing software, technology, customer sales and marketing, and risk management technology hardware and software solutions package under a GSA to a related party. Financial services include providing payment services from one fiat currency to another or to digital assets. It generates maximum revenue from the General support services segment. Geographically operates in USA, UK and Malta, with majority of revenue from United Kingdom (UK).
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.